Compare IDEXX Laboratories, Inc. (IDXX) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B). The key difference: IDEXX Laboratories, Inc. is far larger — about 27.9× YieldMax NVDA Option Income Strategy ETF's market cap, and YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| IDXX | NVDY | |
|---|---|---|
Market Cap | $40.43B | $1.45B |
Volume | 692,164 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $17.21 |
52-Week Low | $504.70 | $11.58 |
Typical Hold Time | 46 Days | 43 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.62, down 3.0% today amid bearish technical signals. The ETF generates income through covered calls on NVIDIA stock but faces structural limitations on upside participation. Recent analyst commentary highlights concerns about NAV erosion despite the attractive 39.7% annualized distribution rate. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as declining NVIDIA volatility reduces option income potential. While weekly distributions provide income, the capped upside and NAV erosion present significant risks for long-term investors. Analyst consensus leans toward Hold ratings, suggesting limited growth prospects despite strong underlying NVIDIA fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
